MILRINONE LACTATE IN DEXTROSE

Other

Brand names: Milrinone Lactate in Dextrose

Intravenous

Mechanism of Action

Pharmacodynamics In patients with heart failure due to depressed myocardial function, milrinone produced a prompt dose and plasma concentration related increase in cardiac output and decreases in pulmonary capillary wedge pressure and vascular resistance, which were accompanied by mild-to-moderate increases in heart rate. Additionally, there is no increased effect on myocardial oxygen consumption. In uncontrolled studies, hemodynamic improvement during intravenous therapy with milrinone was acco

Indications

which may include life threatening ventricular arrhythmias

Contraindications

• CONTRAINDICATIONS Milrinone lactate injection is contraindicated in patients who are hypersensitive to it.

FDA Warnings

WARNINGS Whether given orally or by continuous or intermittent intravenous infusion, milrinone has not been shown to be safe or effective in the longer (greater than 48 hours) treatment of patients with heart failure
In a multicenter trial of 1088 patients with Class III and IV heart failure, long-term oral treatment with milrinone was associated with no improvement in symptoms and an increased risk of hospitalization and death
In this study, patients with Class IV symptoms appeared to be at particular risk of life-threatening cardiovascular reactions
There is no evidence that milrinone given by long-term continuous or intermittent infusion does not carry a similar risk

Known Side Effects

4 documented side effects by frequency

Drug Not Working

>10%

Low Blood Pressure

1-10%

Shortness of Breath

0.1-1%

Nausea

0.1-1%

Community Discussions

No community discussions found for MILRINONE LACTATE IN DEXTROSE yet.

Compare With

0 available comparisons

No comparisons yet.

Formulations

Dosage Forms

Tablet

Route

Intravenous